Eli Lilly (NYSE: LLY) is the top healthcare stock in the world, with a valuation of around $550 billion. Its recently approved weight-loss treatment Zepbound has unlocked a new and exciting growth opportunity for the business. What should investors expect from Eli Lilly over the next five years, and is the stock still worth investing in despite its high valuation?

There's little doubt that Eli Lilly will go after the highly coveted weight-loss market. Market research analysts at Grand View Research see a tremendous opportunity there, projecting the market for global weight management to be worth nearly $300 billion by 2030. That's up from approximately $154 billion today. It's currently growing at a compounded annual growth rate of 9.9%.

Eli Lilly already has an approved weight-loss treatment in Zepbound. In clinical trials, it has helped people lose as much as 26.6% of their body weight after 84 weeks. The company is also working on a once-daily weight-loss pill, orforglipron, which is currently in phase 3 trials. In phase 2, the pill showed that it could help people lose close to 15% of their body weight after 36 weeks.

Continue reading

Source Fool.com